GI cancer paper summaries by Erman Akkus

Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X/Twitter:

1. “A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening/review/.

Reference test: colonoscopy

Sensitivity for stage I, II, or III CRC 87.5% (95% CI, 75.3 to 94.1)

sensitivity for advanced precancerous lesions 13.2% (95% CI, 11.3 to 15.3)

specificity for any advanced neoplasia of 89.6% (95% CI, 88.8 to 90.3)

Specificity for negative colonoscopy (no colorectal cancer, advanced precancerous lesions, or nonadvanced precancerous lesions) 89.9% (95% CI, 89.0 to 90.7).”

Source: Erman Akkus/X

2. “Biomarkers and targeted treatment in pancreatic cancer

Review of an updated perspective

BRCA1/2, MSI, TMB, KRAS, NTRK, NRG, FGFR, BRAF

Drug delivery, cell therapies, vaccines

The POLO trial of olaparib did NOT show significant difference in OS and HRQoL despite longer PFS. No longer life and no better life. Thus? However, limitations of the trial may have prevented the positive effects.”

Source: Erman Akkus/X